Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions

European Journal of Clinical Pharmacology

Volumn 70, Issue 9, 2014, Pages 1115-1122

  Snyder, Ben D ^a   Rowland, Andrew ^a   Polasek, Thomas M ^a   Miners, John O ^a   Doogue, Matthew P ^b  

^a FLINDERS UNIVERSITY   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cytochromes P450; Drug drug interactions; Felodipine; Pharmacokinetics

Indexed keywords

BROMHEXINE; CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; DIGOXIN; FELODIL; FELODIPINE; LOSARTAN; LOSARTAN POTASSIUM; MEPRAZOL; MIDAZOLAM; MULTIDRUG RESISTANCE PROTEIN; OMEPRAZOLE; UNCLASSIFIED DRUG; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED DRUG RELEASE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EVALUATION STUDY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TREATMENT WITHDRAWAL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; GENETICS; GENOTYPE; METABOLISM; YOUNG ADULT;

ADULT; ANTIHYPERTENSIVE AGENTS; CAFFEINE; CALCIUM CHANNEL BLOCKERS; CYTOCHROME P-450 ENZYME INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DEXTROMETHORPHAN; DIGOXIN; DRUG INTERACTIONS; FELODIPINE; FEMALE; GENOTYPE; HUMANS; LOSARTAN; MALE; MIDAZOLAM; OMEPRAZOLE; P-GLYCOPROTEIN; YOUNG ADULT;

EID: 84906236153     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-014-1716-8     Document Type: Article

References (32)

1. National Heart Foundation (2010) Guide to managment of hypertension 2008. Assessing and managing raised blood pressure in adults. Updated 2010. National Heart Foundation, Sydney
2. Bailey DG et al (1991) Interaction of citrus juices with felodipine and nifedipine. Lancet 337(8736):268-269
3. Jalava KM, Olkkola KT, Neuvonen PJ (1997) Itraconazole greatly increases plasma concentrations and effects of felodipine. Clin Pharmacol Ther 61(4):410-415 (Pubitemid 27195943)
4. Capewell S et al (1988) Reduced felodipine bioavailability in patients taking anticonvulsants. Lancet 2(8609):480-482
5. Ma B, Prueksaritanont T, Lin JH(2000)Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 28(2):125-130 (Pubitemid 30068994)
6. Polasek TM et al (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311(3):996-1007 (Pubitemid 39612704)
7. Walsky RL, Gaman EA, Obach RS (2005) Examination of 209 drugs for inhibition of cytochrome P450 2C8. J Clin Pharmacol 45:68-78
8. Smith SR et al (1987) Pharmacokinetic interactions between felodipine and metoprolol. Eur J Clin Pharmacol 31(5):575-578 (Pubitemid 17016939)
9. Meyer BH et al (1992) The effects of felodipine on the pharmacokinetics of diazepam. Int J Clin Pharmacol Ther Toxicol 30(4):117-121
10. Rehnqvist N et al (1987) Pharmacokinetics of felodipine and effect on digoxin plasma levels in patients with heart failure. Drugs 34(Suppl 3):33-42
11. Butani L, Berg G, Makker SP (2002) Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant recipient. Transplantation 73(1):159-160 (Pubitemid 34094708)
12. Polasek TM, Miners JO (2007) In vitro approaches to investigate mechanism-based inactivation of CYP enzymes. Expert Opin Drug Metab Toxicol 3(3):321-329 (Pubitemid 47316027)
13. US Food and Drug Administration, Guidance for industry. Drug interaction studies - study design, data analysis, and implications for dosing, and labeling recommendation. 2012: Rockville, MD
14. European Medicines Agency, Guideline on the investigation of drug interactions. 2012: London, UK
15. Lahiri DK et al (1992) A non-organic and non-enzymatic extraction method gives higher yields of genomic DNA from whole-blood samples than do nine other methods tested. J Biochem Biophys Methods 25(4):192-203
16. Wright GEB et al (2010) Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population. Ann Hum Genet 74(4):340-350
17. Hsiao CL, Wu YC, Hsu KY (2011) Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. Arzneimittelforschung 61(8):444-451
18. Olkkola KT, Backman JT, Neuvonen PJ (1994)Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther 55(5):481-485 (Pubitemid 24192233)
19. Kang BC et al (2002) Influence of fluconazole on the pharmacokientics of omeprazole in healthy volunteers. Biopharm Drug Dispos 23:77-81 (Pubitemid 34521110)
20. Harder S et al (1988) 4-quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol 35(6):651-656 (Pubitemid 19000284)
21. Williamson KM et al (1998) Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 63(3):316-323 (Pubitemid 28182229)
22. Greiner B et al (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig 104(2):147-153
23. Ryu JY et al (2007) Development of the "Inje cocktail" for highthroughput evaluation of five human cytochrome P450 isoforms in vivo. Clin Pharmacol Ther 82(5):531-540 (Pubitemid 47622519)
24. Kirby B et al (2006) Simultaneous measurement of in vivo pglycoprotein and cytochrome P450 3A activities. J Clin Pharmacol 46(11):1313-1319 (Pubitemid 44564360)
25. Fuhr U, Jetter A, Kirchheiner J (2007) Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 81(2):270-283 (Pubitemid 46174825)
26. Andersson T (1996) Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. Clin Pharmacokinet 31(1):9-28
27. Sica DA, Gehr TW, Ghosh S (2005) Clinical pharmacokinetics of losartan. Clin Pharmacokinet 44(8):797-814 (Pubitemid 41126929)
28. De Smet M et al (1995) Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. Br J Clin Pharmacol 40(6):571-575 (Pubitemid 26005562)
29. Oosterhuis B et al (1991) Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. Br J Clin Pharmacol 32(5):569-572
30. Polasek T et al (2011) Perpetrators of pharmacokinetic drug-drug interactions from altered cytochrome P450 activity: a criteria-based assessment. Br J Clin Pharmacol 71(5):727-736
31. Bengtsson-Hasselgren B et al (1990) Acute effects of felodipine and nifedipine on hepatic and forearm blood flow in healthy men. Eur J Clin Pharmacol 38(6):529-533 (Pubitemid 20206022)
32. Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications. 3rd ed. Williams & Wilkins, Baltimore